Abstract:Background Type 1 diabetes mellitus (T1DM) is caused by immune cell-mediated β-cell dysfunction. In recent decades, N6-methyladenosine (m6A) has attracted widespread attention in the scientific research field because it plays vital roles in the pathogenesis of immunity-related diseases, including autoimmune diseases. However, neither the m6A modification profile nor the potential role it plays in T1DM pathogenesis has been investigated to date. Materials and Methods An m6A mRNA epitranscriptomic microarray analysis was performed to analyze m6A regulator expression patterns and m6A methylation patterns in immune cells of T1DM patients (n=6) and healthy individuals (n=6). A bioinformatics analysis was subsequently performed to explore the potential biological functions and signaling pathways underlying T1DM pathogenesis. Furthermore, mRNA expression and m6A methylation levels were subsequently verified by qRT–PCR and methylated RNA immunoprecipitation–qPCR (MeRIP–qPCR), respectively, in the T1DM and healthy groups (n=6 per group). Results Among the multiple m6A regulators, METTL3 and IGF2BP2 had significantly downregulated expression, and YTHDC1 and HNRNPA2B1 had significantly upregulated expression in the T1DM group relative to the healthy group. The microarray analysis revealed 4247 differentially methylated transcripts, including 932 hypermethylated and 3315 hypomethylated transcripts, and 4264 differentially expressed transcripts, including 1818 upregulated transcripts and 2446 downregulated transcripts in the T1DM group relative to the healthy group. An association analysis between methylation and gene expression demonstrated that the expression of 590 hypermethylated transcripts was upregulated, and that of 1890 hypomethylated transcripts was downregulated. Pearson correlation analysis showed significant correlations between the expression levels of differentially expressed m6A regulators and the methylation levels of differentially methylated transcripts and significant correlations between the expression levels of differentially expressed m6A regulators and that of differentially expressed transcripts. Moreover, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses demonstrated that differentially methylated transcripts were involved in pathways related to immunity, including some closely associated with T1DM. Conclusions Our study presents m6A regulator expression patterns and m6A methylation patterns of immune cells in T1DM, showing that the m6A mark and m6A regulators are promising targets for T1DM diagnosis and treatment.

DecreasedN6-Methyladenosine in Peripheral Blood RNA from Diabetic Patients is Associated WithFTOExpression Rather ThanALKBH5

Decreased N(6)-methyladenosine in peripheral blood RNA from diabetic patients is associated with FTO expression rather than ALKBH5.

The Pro~(12) → Ala Substitution in PPARγ_2 Gene May Be a Protective Factor for the Development of Type 2(diabetes) in Chinese Han Population

N6-Methyladenosine Demethylase FTO Controlsmacrophage Homeostasis in Diabetic Vasculopathy

Comprehensive analysis of the m6A demethylase FTO in endothelial dysfunction by MeRIP sequencing

Changes of m6A Regulatory Proteins and Nrf2 Signaling Molecules in Liver Tissue of Type 2 Diabetes Mellitus Rats

The role of m 6 A modification in type 2 diabetes: a systematic review and integrative analysis

N6-methyladenosine demethylase fat mass and obesity-associated protein suppresses hyperglycemia-induced endothelial cell injury by inhibiting reactive oxygen species formation via autophagy promotion

U‐shaped Association Between Serum IGF2BP3 and T2DM: A Cross‐sectional Study in Chinese Population

Changes in N6-Methyladenosine Modification Modulate Diabetic Cardiomyopathy by Reducing Myocardial Fibrosis and Myocyte Hypertrophy

N 6 -Methyladenosine Modification-Mediated Mrna Metabolism is Essential for Human Pancreatic Lineage Specification and Islet Organogenesis

N 6-Methyladenosine demethylase FTO controls macrophage homeostasis in diabetic vasculopathy

The m6A methylation profiles of immune cells in type 1 diabetes mellitus

Recent Advances of M6a Demethylases Inhibitors and Their Biological Functions in Human Diseases

Analysis of N6-Methyladenosine Methylation Modification in Fructose-Induced Non-Alcoholic Fatty Liver Disease

Changes of RNA m6A/m5C Modification Regulatory Molecules in Ferroptosis of T2DM Rat Pancreas

��清igf2bp3与2型糖尿病的u型关联:一项中国人群横断面研究

Genome-Wide Identification of N6-Methyladenosine Associated SNPs As Potential Functional Variants for Type 1 Diabetes

Altered N6-Methyladenosine Modification Patterns and Transcript Profiles Contributes to Cognitive Dysfunction in High-Fat Induced Diabetic Mice

Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma

N6-methyladenosine RNA methylation in diabetic kidney disease